Prognostic value of fluorine-18 fludeoxyglucose positron emission tomography parameters differs according to primary tumour location in small-cell lung cancer

Abstract

Objective: To investigate the prognostic value of fluorine-18 fludeoxyglucose (FDG) positron emission tomography (PET) parameters for small-cell lung cancer (SCLC), according to the primary tumour location, adjusted by conventional prognostic factors. Methods: From 2008 to 2013, we enrolled consecutive patients with histologically proven SCLC, who had undergone FDG-PET/CT prior to initial therapy. The primary tumour location was categorized into central or peripheral types. PET parameters and clinical variables were evaluated using univariate and multivariate analysis. Results: A total of 69 patients were enrolled in this study; 28 of these patients were categorized as having the central type and 41 patients as having the peripheral type. In univariate analysis, stage, serum neuron-specific enolase, whole-body metabolic tumour volume (WB-MTV) and whole-body total lesion glycolysis (WB-TLG) were found to be significant in both types of patients. In multivariate analysis, the independent prognostic factor was found to be stage in the central type, but WB-MTV and WB-TLG in the peripheral type. Kaplan-Meier analysis demonstrated that patients with peripheral type with limited disease and low WB-MTV or WB-TLG showed significantly better overall survival than all of the other groups (p , 0.0083). Conclusion: The FDG-PET volumetric parameters were demonstrated to be significant and independent prognostic factors in patients with peripheral type of SCLC, while stage was the only independent prognostic factor in patients with central type of SCLC. Advances in knowledge: FDG-PET is a non-invasive method that could potentially be used to estimate the prognosis of patients, especially those with peripheraltype SCLC.

Clinical outcomes of surgically resected combined small cell lung cancer: a two-institutional experience

“…Out results showed that the majority of c-SCLC patients had nodal positive disease. Previous report showed that PET-CT was more sensitive than other imaging modalities with respect to the pretreatment staging of SCLCs (20,21). A retrospectively nationwide study showed that clinical stage had a poor consistency with pathological stage (9).…”

Prognostic value of metabolic tumour volume and total lesion glycolysis measured by 18F‐fluorodeoxyglucose positron emission tomography/computed tomography in small cell lung cancer: A systematic review and meta‐analysis

“…We reviewed the remaining full text for nine articles; one study that calculated the HRs by a 10‐cm 3 increase in MTV and TLG was excluded, while one study was excluded because it did not provide data for HRs and lacked sufficient information to enable a calculation of the HR with corresponding 95% CI . The remaining seven articles all conformed to the inclusion criteria and had sufficient information to allow calculation of HRs . Both MTV and TLG were measured in three studies .…”

“…The remaining seven articles all conformed to the inclusion criteria and had sufficient information to allow calculation of HRs . Both MTV and TLG were measured in three studies . while, only MTV was measured in the other four studies .…”

“…One study (Nobashi et al .) reported the HRs separately for patients with central or peripheral types of SCLC: we obtained the HRs for the whole group directly from the authors . In the seven studies eligible for our meta‐analysis, the endpoints reported were overall survival (OS) in two studies, progression‐free survival (PFS) in one study and both OS and PFS in four studies.…”

“…In the seven studies eligible for our meta‐analysis, the endpoints reported were overall survival (OS) in two studies, progression‐free survival (PFS) in one study and both OS and PFS in four studies. Three studies reported on the prognostic value of whole‐body MTV (MTV WB ), one with TLG WB as well . This included primary tumour, lymph nodes, and distant metastases.…”